Michelle Maust, MD
Psychiatry · Raleigh, NCNPI 1811283500
Payments from drug & device makers
Across 44 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$149
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108
- Teva Pharmaceuticals USA, Inc.$88
- Otsuka America Pharmaceutical, Inc.$85
- Neos Therapeutics, LP$76
- Jazz Pharmaceuticals Inc.$67
- plus $266 from 7 others
Across 5 payments — averaging $231.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Food & beverage$79394%
- Education$476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $149 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Neos Therapeutics, LP | 5 | $76 |
| Jazz Pharmaceuticals Inc. | 4 | $67 |
| AbbVie(2 entities) | 4 | $58 |
| Johnson & Johnson | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
| Lundbeck LLC | 2 | $26 |
| Neuronetics, Inc. | 1 | $13 |
How this compares
$840 in reported general payments places this provider in the 70th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 23 | $146,458 |
| Risperdal ConstaRisperidone Microspheres | 49 | $38,993 |
| VraylarCariprazine Hcl | 25 | $34,513 |
| TrintellixVortioxetine Hydrobromide | 32 | $25,545 |
| BelsomraSuvorexant | 23 | $10,066 |
| Lurasidone Hcl | 12 | $6,763 |
| Paliperidone ErPaliperidone | 20 | $2,485 |
| Aripiprazole | 47 | $2,128 |
| Quetiapine Fumarate | 116 | $1,042 |
| Ziprasidone Hcl | 15 | $766 |
| Propranolol Hcl ErPropranolol Hcl | 20 | $725 |
| Clonazepam | 91 | $632 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $595 |
| Gabapentin | 40 | $588 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $88 | $146,45823 claims |
| Johnson & JohnsonRisperdal Consta | $49 | $38,99349 claims |
| AbbVieVraylar | $58 | $34,51325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $149 | $25,54532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Raleigh
- Richard WeislerRaleigh$1.2M
- Robert MilletRaleigh$517K
- Ashwin PatkarRaleigh$170K
- Mona GuptaRaleigh$88K
- Kellie TolinRaleigh$31K
- Celso LobaoRaleigh$28K
- Elizabeth CoxRaleigh$24K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.